Semaglutide and Physical Activity for Obesity and Multimorbidity

Sponsor
Hvidovre University Hospital
Study ID
NCT06234111
Status
Active Not Recruiting

Conditions

  • Multimorbidity
  • Obesity
  • Obesity Morbid

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide 2.4 mg, total diet replacement, behavioural intervention — COMBINATION_PRODUCT
    Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.

Study Details

The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients with severe obesity and multimorbidity. This study is explorative and therefore does not include hypothesis testing.

Key Dates

Start date
Feb 20, 2024
Status verified
Dec 2024
Primary completion
Oct 31, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: Patients with severe obesity and multimorbidity
    Patients with morbid obesity (mainly class II and III) with multiple chronic conditions. Most patients are initially referred for bariatric surgery, but are deemed ineligible for various reasons (typically inability to independently induce weight loss, severe mental disease, eating disorder, and serious comorbidity).

Primary Outcome Measure

Habitual physical activity [ Time Frame: Baseline (± 2 weeks), 4 months (± 2 weeks) and 24 months (± 2 weeks). ]

Related Studies